zacks.com · 1 jul

Can HCA's Gene Therapy Milestone Drive Long-Term Growth?

HCA Healthcare highlights promising pediatric CRISPR gene therapy results as expanding specialty care and research investments support its long-term growth strategy.

businesswire.com · 29 jun

HCA Healthcare Announces New England Journal of Medicine Study Highlighting Advances in CRISPR-based Therapy for Children

NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today announced new research published in The New England Journal of Medicine (NEJM) demonstrating promising results from a gene-editing therapy being investigated in children ages 5-11 with severe sickle cell disease and transfusion-dependent beta thalassemia. Sickle cell disease and beta thalassemia are inherited blood disorders that can cause serious, lifelong complications b.

zacks.com · 26 jun

HCA Healthcare (HCA) is a Top-Ranked Growth Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com · 25 jun

Why HCA Healthcare (HCA) is a Top Stock for the Long-Term

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.

zacks.com · 24 jun

Why HCA Healthcare (HCA) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

marketbeat.com · 15 jun

Healthcare Added 35,200 Jobs—3 Stocks Positioned to Benefit

The May Jobs report told a familiar story for investors in healthcare stocks. The sector added 35,200 positions last month, led by ambulatory health services at 25,700 and hospitals at 6,000.

gurufocus.com · 10 jun

Is HCA Undervalued? DCF Says Worth $765

On June 10, 2026, we present a detailed DCF analysis for HCA Healthcare Inc (HCA), a company currently facing a challenging price performance context with a yea

businesswire.com · 9 jun

Mission Bio and Human Cell Atlas Collaborate to Expand Access to Single-Cell Multiomics Ahead of HCA 2026 Meeting

SAN FRANCISCO--(BUSINESS WIRE)--Mission Bio, the leader in single-cell multiomics solutions, today announced a collaboration with the Human Cell Atlas (HCA), a global consortium working to create comprehensive reference maps of all human cells to advance the understanding, diagnosis, and treatment of disease. The announcement comes ahead of the upcoming Human Cell Atlas General Meeting 2026, taking place June 16–18 in Boston, where Mission Bio will participate alongside leading researchers and.